Global DMX-200 Small-Molecule CCR2 Antagonist Market Growth (Status and Outlook) 2026-2032
The global DMX-200 Small-Molecule CCR2 Antagonist market size is predicted to grow from US$ 1.47 million in 2025 to US$ 53.52 million in 2032; it is expected to grow at a CAGR of 62.2% from 2026 to 2032.
DMX-200 Small-Molecule CCR2 Antagonist refers to an oral small-molecule drug asset targeting the chemokine receptor 2 (CCR2), with DMX-200 (repagermanium / QYTOVRA?) as the core product covered in this study. This topic focuses on the clinical-stage use value and potential post-approval sales opportunity of DMX-200 in the treatment of Focal Segmental Glomerulosclerosis (FSGS). By modulating CCR2-related inflammatory pathways, DMX-200 is positioned as a potential add-on therapy to existing background treatment for FSGS patients, aiming to reduce proteinuria, improve kidney disease progression-related indicators, and address unmet clinical needs in rare kidney diseases.
Based on our research, DMX-200 Small-Molecule CCR2 Antagonist should be positioned as a late-stage orphan drug product opportunity rather than a mature commercial pharmaceutical market. The product focuses on Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease with clear unmet medical needs. Its value proposition is supported by the oral small-molecule format, the CCR2-related mechanism, and its potential positioning as an add-on therapy to existing background treatment. As DMX-200 remains in pivotal Phase 3 development, near-term market sizing should not be treated as mature product revenue. A more appropriate approach is to estimate conservative clinical-stage use value in the short term and potential post-approval sales opportunity in the longer term.
From the supply structure perspective, DMX-200 is not a standardized drug market with multiple parallel suppliers. It is a single core asset controlled by Dimerix and advanced through regional licensing partners for global commercialization preparation. On June 16, 2026, Everest Medicines announced through the Hong Kong Stock Exchange that it had entered into an agreement with Dimerix Limited to obtain development and commercialization rights for DMX-200 in Greater China, South Korea, and certain Southeast Asian countries. The significance of this transaction is not merely the addition of one regional partner, but the extension of DMX-200?s commercialization footprint into key Asian markets and its transition from a clinical pipeline asset toward regional registration, market access, and launch preparation.
From the policy and outlook perspective, DMX-200 benefits from a clear orphan drug profile, and orphan drug-related incentives may help reduce development and commercialization uncertainty in rare diseases. However, such regulatory status does not represent marketing approval or guaranteed sales. The key variables for future value creation remain the final Phase 3 results, approval timelines in major markets, execution capability of regional licensees, competitor launch dynamics, and reimbursement acceptance. Overall, DMX-200 can be viewed as a promising late-stage orphan drug asset, with conservative near-term assumptions and meaningful long-term upside if clinical and regulatory milestones are achieved.
This report presents a comprehensive overview, market shares, and growth opportunities of DMX-200 Small-Molecule CCR2 Antagonist market by product type, application, key players and key regions and countries.
Segmentation by Type:
DMX-200 Small-Molecule CCR2 Antagonist refers to an oral small-molecule drug asset targeting the chemokine receptor 2 (CCR2), with DMX-200 (repagermanium / QYTOVRA?) as the core product covered in this study. This topic focuses on the clinical-stage use value and potential post-approval sales opportunity of DMX-200 in the treatment of Focal Segmental Glomerulosclerosis (FSGS). By modulating CCR2-related inflammatory pathways, DMX-200 is positioned as a potential add-on therapy to existing background treatment for FSGS patients, aiming to reduce proteinuria, improve kidney disease progression-related indicators, and address unmet clinical needs in rare kidney diseases.
Based on our research, DMX-200 Small-Molecule CCR2 Antagonist should be positioned as a late-stage orphan drug product opportunity rather than a mature commercial pharmaceutical market. The product focuses on Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease with clear unmet medical needs. Its value proposition is supported by the oral small-molecule format, the CCR2-related mechanism, and its potential positioning as an add-on therapy to existing background treatment. As DMX-200 remains in pivotal Phase 3 development, near-term market sizing should not be treated as mature product revenue. A more appropriate approach is to estimate conservative clinical-stage use value in the short term and potential post-approval sales opportunity in the longer term.
From the supply structure perspective, DMX-200 is not a standardized drug market with multiple parallel suppliers. It is a single core asset controlled by Dimerix and advanced through regional licensing partners for global commercialization preparation. On June 16, 2026, Everest Medicines announced through the Hong Kong Stock Exchange that it had entered into an agreement with Dimerix Limited to obtain development and commercialization rights for DMX-200 in Greater China, South Korea, and certain Southeast Asian countries. The significance of this transaction is not merely the addition of one regional partner, but the extension of DMX-200?s commercialization footprint into key Asian markets and its transition from a clinical pipeline asset toward regional registration, market access, and launch preparation.
From the policy and outlook perspective, DMX-200 benefits from a clear orphan drug profile, and orphan drug-related incentives may help reduce development and commercialization uncertainty in rare diseases. However, such regulatory status does not represent marketing approval or guaranteed sales. The key variables for future value creation remain the final Phase 3 results, approval timelines in major markets, execution capability of regional licensees, competitor launch dynamics, and reimbursement acceptance. Overall, DMX-200 can be viewed as a promising late-stage orphan drug asset, with conservative near-term assumptions and meaningful long-term upside if clinical and regulatory milestones are achieved.
This report presents a comprehensive overview, market shares, and growth opportunities of DMX-200 Small-Molecule CCR2 Antagonist market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Oral Small-Molecule CCR2 Antagonist
- Other
- Adult Patients
- Adolescent Patients
- Other
- Focal Segmental Glomerulosclerosis, FSGS
- Other
- United States
- China%li%
- Europe
- Other regions
- Japan
- South Korea
- Southeast Asia
- Rest of world
- Dimerix Limited
- BioMarin Pharmaceutical Inc.
- ADVANZ PHARMA Corp. Limited
- Taiba Middle East FZ LLC
- FUSO Pharmaceutical Industries, Ltd.
- Everest Medicines Limited
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global DMX-200 Small-Molecule CCR2 Antagonist Market Size 2026-2032
2.1.2 DMX-200 Small-Molecule CCR2 Antagonist Market Size CAGR by Region
2.2 DMX-200 Small-Molecule CCR2 Antagonist Segment by Type
2.2.1 Oral Small-Molecule CCR2 Antagonist
2.2.2 Other
2.2.3 DMX-200 Small-Molecule CCR2 Antagonist Market Size by Type
2.2.3.1 Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Type (2026-2032)
2.2.3.2 Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Growth Rate by Type (2026-2032)
2.3 DMX-200 Small-Molecule CCR2 Antagonist Segment by Patient Population
2.3.1 Adult Patients
2.3.2 Adolescent Patients
2.3.3 Other
2.3.4 DMX-200 Small-Molecule CCR2 Antagonist Market Size by Patient Population
2.3.4.1 Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Patient Population (2026-2032)
2.3.4.2 Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Growth Rate by Patient Population (2026-2032)
2.4 DMX-200 Small-Molecule CCR2 Antagonist Segment by Application
2.4.1 Focal Segmental Glomerulosclerosis, FSGS
2.4.2 Other
2.4.3 DMX-200 Small-Molecule CCR2 Antagonist Market Size by Application (2026-2032)
2.4.3.1 Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Application (2026-2032)
2.4.3.2 Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Growth Rate by Application (2026-2032)
3 DMX-200 SMALL-MOLECULE CCR2 ANTAGONIST KEY PLAYERS
3.1 Date of Key Players Enter into DMX-200 Small-Molecule CCR2 Antagonist
3.2 Key Players DMX-200 Small-Molecule CCR2 Antagonist Product Offered
3.3 Key Players DMX-200 Small-Molecule CCR2 Antagonist Funding/Investment Analysis
3.4 Funding/Investment
3.4.1 Funding/Investment by Regions
3.4.2 Funding/Investment by End-Industry
3.5 Key Players DMX-200 Small-Molecule CCR2 Antagonist Valuation & Market Capitalization
3.6 Key Players Mergers & Acquisitions, Expansion Plans
3.7 Market Ranking
3.8 New Product/Technology Launches
3.9 Partnerships, Agreements, and Collaborations
3.10 Mergers and Acquisitions
4 DMX-200 SMALL-MOLECULE CCR2 ANTAGONIST BY REGIONS
4.1 DMX-200 Small-Molecule CCR2 Antagonist Market Size by Regions (2026-2032)
4.2 United States DMX-200 Small-Molecule CCR2 Antagonist Market Size Growth (2026-2032)
4.3 China DMX-200 Small-Molecule CCR2 Antagonist Market Size Growth (2026-2032)
4.4 Europe DMX-200 Small-Molecule CCR2 Antagonist Market Size Growth (2026-2032)
4.5 Rest of World DMX-200 Small-Molecule CCR2 Antagonist Market Size Growth (2026-2032)
5 UNITED STATES
5.1 United States DMX-200 Small-Molecule CCR2 Antagonist Market Size by Type (2026-2032)
5.2 United States DMX-200 Small-Molecule CCR2 Antagonist Market Size by Application (2026-2032)
6 EUROPE
6.1 Europe DMX-200 Small-Molecule CCR2 Antagonist Market Size by Type (2026-2032)
6.2 Europe DMX-200 Small-Molecule CCR2 Antagonist Market Size by Application (2026-2032)
7 CHINA
7.1 China DMX-200 Small-Molecule CCR2 Antagonist Market Size by Type (2026-2032)
7.2 China DMX-200 Small-Molecule CCR2 Antagonist Market Size by Application (2026-2032)
8 REST OF WORLD
8.1 Rest of World DMX-200 Small-Molecule CCR2 Antagonist Market Size by Type (2026-2032)
8.2 Rest of World DMX-200 Small-Molecule CCR2 Antagonist Market Size by Application (2026-2032)
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 KEY INVESTORS IN DMX-200 SMALL-MOLECULE CCR2 ANTAGONIST
10.1 Company A
10.1.1 Company A Company Details
10.1.2 Company Description
10.1.3 Companies Invested by Company A
10.1.4 Company A Key Development and Market Layout
10.2 Company B
10.2.1 Company B Company Details
10.2.2 Company Description
10.2.3 Companies Invested by Company B
10.2.4 Company B Key Development and Market Layout
10.3 Company C
10.3.1 Company C Company Details
10.3.2 Company Description
10.3.3 Companies Invested by Company C
10.3.4 Company C Key Development and Market Layout
10.4 Company D
10.5 ??
11 KEY PLAYERS ANALYSIS
11.1 Dimerix Limited
11.1.1 Dimerix Limited Company Details
11.1.2 Dimerix Limited DMX-200 Small-Molecule CCR2 Antagonist Product Offered
11.1.3 Dimerix Limited DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
11.1.4 Dimerix Limited Main Business Overview
11.1.5 Dimerix Limited News
11.2 BioMarin Pharmaceutical Inc.
11.2.1 BioMarin Pharmaceutical Inc. Company Details
11.2.2 BioMarin Pharmaceutical Inc. DMX-200 Small-Molecule CCR2 Antagonist Product Offered
11.2.3 BioMarin Pharmaceutical Inc. DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
11.2.4 BioMarin Pharmaceutical Inc. Main Business Overview
11.2.5 BioMarin Pharmaceutical Inc. News
11.3 ADVANZ PHARMA Corp. Limited
11.3.1 ADVANZ PHARMA Corp. Limited Company Details
11.3.2 ADVANZ PHARMA Corp. Limited DMX-200 Small-Molecule CCR2 Antagonist Product Offered
11.3.3 ADVANZ PHARMA Corp. Limited DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
11.3.4 ADVANZ PHARMA Corp. Limited Main Business Overview
11.3.5 ADVANZ PHARMA Corp. Limited News
11.4 Taiba Middle East FZ LLC
11.4.1 Taiba Middle East FZ LLC Company Details
11.4.2 Taiba Middle East FZ LLC DMX-200 Small-Molecule CCR2 Antagonist Product Offered
11.4.3 Taiba Middle East FZ LLC DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
11.4.4 Taiba Middle East FZ LLC Main Business Overview
11.4.5 Taiba Middle East FZ LLC News
11.5 FUSO Pharmaceutical Industries, Ltd.
11.5.1 FUSO Pharmaceutical Industries, Ltd. Company Details
11.5.2 FUSO Pharmaceutical Industries, Ltd. DMX-200 Small-Molecule CCR2 Antagonist Product Offered
11.5.3 FUSO Pharmaceutical Industries, Ltd. DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
11.5.4 FUSO Pharmaceutical Industries, Ltd. Main Business Overview
11.5.5 FUSO Pharmaceutical Industries, Ltd. News
11.6 Everest Medicines Limited
11.6.1 Everest Medicines Limited Company Details
11.6.2 Everest Medicines Limited DMX-200 Small-Molecule CCR2 Antagonist Product Offered
11.6.3 Everest Medicines Limited DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
11.6.4 Everest Medicines Limited Main Business Overview
11.6.5 Everest Medicines Limited News
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global DMX-200 Small-Molecule CCR2 Antagonist Market Size 2026-2032
2.1.2 DMX-200 Small-Molecule CCR2 Antagonist Market Size CAGR by Region
2.2 DMX-200 Small-Molecule CCR2 Antagonist Segment by Type
2.2.1 Oral Small-Molecule CCR2 Antagonist
2.2.2 Other
2.2.3 DMX-200 Small-Molecule CCR2 Antagonist Market Size by Type
2.2.3.1 Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Type (2026-2032)
2.2.3.2 Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Growth Rate by Type (2026-2032)
2.3 DMX-200 Small-Molecule CCR2 Antagonist Segment by Patient Population
2.3.1 Adult Patients
2.3.2 Adolescent Patients
2.3.3 Other
2.3.4 DMX-200 Small-Molecule CCR2 Antagonist Market Size by Patient Population
2.3.4.1 Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Patient Population (2026-2032)
2.3.4.2 Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Growth Rate by Patient Population (2026-2032)
2.4 DMX-200 Small-Molecule CCR2 Antagonist Segment by Application
2.4.1 Focal Segmental Glomerulosclerosis, FSGS
2.4.2 Other
2.4.3 DMX-200 Small-Molecule CCR2 Antagonist Market Size by Application (2026-2032)
2.4.3.1 Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Application (2026-2032)
2.4.3.2 Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Growth Rate by Application (2026-2032)
3 DMX-200 SMALL-MOLECULE CCR2 ANTAGONIST KEY PLAYERS
3.1 Date of Key Players Enter into DMX-200 Small-Molecule CCR2 Antagonist
3.2 Key Players DMX-200 Small-Molecule CCR2 Antagonist Product Offered
3.3 Key Players DMX-200 Small-Molecule CCR2 Antagonist Funding/Investment Analysis
3.4 Funding/Investment
3.4.1 Funding/Investment by Regions
3.4.2 Funding/Investment by End-Industry
3.5 Key Players DMX-200 Small-Molecule CCR2 Antagonist Valuation & Market Capitalization
3.6 Key Players Mergers & Acquisitions, Expansion Plans
3.7 Market Ranking
3.8 New Product/Technology Launches
3.9 Partnerships, Agreements, and Collaborations
3.10 Mergers and Acquisitions
4 DMX-200 SMALL-MOLECULE CCR2 ANTAGONIST BY REGIONS
4.1 DMX-200 Small-Molecule CCR2 Antagonist Market Size by Regions (2026-2032)
4.2 United States DMX-200 Small-Molecule CCR2 Antagonist Market Size Growth (2026-2032)
4.3 China DMX-200 Small-Molecule CCR2 Antagonist Market Size Growth (2026-2032)
4.4 Europe DMX-200 Small-Molecule CCR2 Antagonist Market Size Growth (2026-2032)
4.5 Rest of World DMX-200 Small-Molecule CCR2 Antagonist Market Size Growth (2026-2032)
5 UNITED STATES
5.1 United States DMX-200 Small-Molecule CCR2 Antagonist Market Size by Type (2026-2032)
5.2 United States DMX-200 Small-Molecule CCR2 Antagonist Market Size by Application (2026-2032)
6 EUROPE
6.1 Europe DMX-200 Small-Molecule CCR2 Antagonist Market Size by Type (2026-2032)
6.2 Europe DMX-200 Small-Molecule CCR2 Antagonist Market Size by Application (2026-2032)
7 CHINA
7.1 China DMX-200 Small-Molecule CCR2 Antagonist Market Size by Type (2026-2032)
7.2 China DMX-200 Small-Molecule CCR2 Antagonist Market Size by Application (2026-2032)
8 REST OF WORLD
8.1 Rest of World DMX-200 Small-Molecule CCR2 Antagonist Market Size by Type (2026-2032)
8.2 Rest of World DMX-200 Small-Molecule CCR2 Antagonist Market Size by Application (2026-2032)
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 KEY INVESTORS IN DMX-200 SMALL-MOLECULE CCR2 ANTAGONIST
10.1 Company A
10.1.1 Company A Company Details
10.1.2 Company Description
10.1.3 Companies Invested by Company A
10.1.4 Company A Key Development and Market Layout
10.2 Company B
10.2.1 Company B Company Details
10.2.2 Company Description
10.2.3 Companies Invested by Company B
10.2.4 Company B Key Development and Market Layout
10.3 Company C
10.3.1 Company C Company Details
10.3.2 Company Description
10.3.3 Companies Invested by Company C
10.3.4 Company C Key Development and Market Layout
10.4 Company D
10.5 ??
11 KEY PLAYERS ANALYSIS
11.1 Dimerix Limited
11.1.1 Dimerix Limited Company Details
11.1.2 Dimerix Limited DMX-200 Small-Molecule CCR2 Antagonist Product Offered
11.1.3 Dimerix Limited DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
11.1.4 Dimerix Limited Main Business Overview
11.1.5 Dimerix Limited News
11.2 BioMarin Pharmaceutical Inc.
11.2.1 BioMarin Pharmaceutical Inc. Company Details
11.2.2 BioMarin Pharmaceutical Inc. DMX-200 Small-Molecule CCR2 Antagonist Product Offered
11.2.3 BioMarin Pharmaceutical Inc. DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
11.2.4 BioMarin Pharmaceutical Inc. Main Business Overview
11.2.5 BioMarin Pharmaceutical Inc. News
11.3 ADVANZ PHARMA Corp. Limited
11.3.1 ADVANZ PHARMA Corp. Limited Company Details
11.3.2 ADVANZ PHARMA Corp. Limited DMX-200 Small-Molecule CCR2 Antagonist Product Offered
11.3.3 ADVANZ PHARMA Corp. Limited DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
11.3.4 ADVANZ PHARMA Corp. Limited Main Business Overview
11.3.5 ADVANZ PHARMA Corp. Limited News
11.4 Taiba Middle East FZ LLC
11.4.1 Taiba Middle East FZ LLC Company Details
11.4.2 Taiba Middle East FZ LLC DMX-200 Small-Molecule CCR2 Antagonist Product Offered
11.4.3 Taiba Middle East FZ LLC DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
11.4.4 Taiba Middle East FZ LLC Main Business Overview
11.4.5 Taiba Middle East FZ LLC News
11.5 FUSO Pharmaceutical Industries, Ltd.
11.5.1 FUSO Pharmaceutical Industries, Ltd. Company Details
11.5.2 FUSO Pharmaceutical Industries, Ltd. DMX-200 Small-Molecule CCR2 Antagonist Product Offered
11.5.3 FUSO Pharmaceutical Industries, Ltd. DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
11.5.4 FUSO Pharmaceutical Industries, Ltd. Main Business Overview
11.5.5 FUSO Pharmaceutical Industries, Ltd. News
11.6 Everest Medicines Limited
11.6.1 Everest Medicines Limited Company Details
11.6.2 Everest Medicines Limited DMX-200 Small-Molecule CCR2 Antagonist Product Offered
11.6.3 Everest Medicines Limited DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
11.6.4 Everest Medicines Limited Main Business Overview
11.6.5 Everest Medicines Limited News
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. DMX-200 Small-Molecule CCR2 Antagonist Market Size CAGR by Region (2026-2032) ($ millions)
Table 2. Major Players of Oral Small-Molecule CCR2 Antagonist
Table 3. Major Players of Other
Table 4. Global Market Size by Type (2026-2032) ($ millions)
Table 5. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Type (2026-2032)
Table 6. Major Players of Adult Patients
Table 7. Major Players of Adolescent Patients
Table 8. Major Players of Other
Table 9. Global Market Size by Patient Population (2026-2032) ($ millions)
Table 10. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Patient Population (2026-2032)
Table 11. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size by Application (2026-2032) ($ millions)
Table 12. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Application (2026-2032)
Table 13. Date of Global Key Players Enter into DMX-200 Small-Molecule CCR2 Antagonist Market
Table 14. Global Key Players DMX-200 Small-Molecule CCR2 Antagonist Product Offered
Table 15. Key Players DMX-200 Small-Molecule CCR2 Antagonist Funding/Investment (Million USD)
Table 16. Funding/Investment by Regions
Table 17. Funding/Investment by End-Industry
Table 18. Key Players DMX-200 Small-Molecule CCR2 Antagonist Valuation & Market Capitalization (Million USD)
Table 19. Key Players Mergers & Acquisitions, Expansion Plans
Table 20. DMX-200 Small-Molecule CCR2 Antagonist New Product/Technology Launches
Table 21. DMX-200 Small-Molecule CCR2 Antagonist Industry Partnerships, Agreements, and Collaborations
Table 22. DMX-200 Small-Molecule CCR2 Antagonist Industry Mergers and Acquisitions
Table 23. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size by Regions 2026-2032 ($ millions)
Table 24. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Regions 2026-2032
Table 25. United States DMX-200 Small-Molecule CCR2 Antagonist Market Size by Type (2026-2032) ($ millions)
Table 26. United States DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Type (2026-2032)
Table 27. United States DMX-200 Small-Molecule CCR2 Antagonist Market Size by Application (2026-2032) ($ millions)
Table 28. United States DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Application (2026-2032)
Table 29. Europe DMX-200 Small-Molecule CCR2 Antagonist Market Size by Type (2026-2032) ($ millions)
Table 30. Europe DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Type (2026-2032)
Table 31. Europe DMX-200 Small-Molecule CCR2 Antagonist Market Size by Application (2026-2032) ($ millions)
Table 32. Europe DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Application (2026-2032)
Table 33. China DMX-200 Small-Molecule CCR2 Antagonist Market Size by Type (2026-2032) ($ millions)
Table 34. China DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Type (2026-2032)
Table 35. China DMX-200 Small-Molecule CCR2 Antagonist Market Size by Application (2026-2032) ($ millions)
Table 36. China DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Application (2026-2032)
Table 37. Rest of World DMX-200 Small-Molecule CCR2 Antagonist Market Size by Type (2026-2032) ($ millions)
Table 38. Rest of World DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Type (2026-2032)
Table 39. Rest of World DMX-200 Small-Molecule CCR2 Antagonist Market Size by Application (2026-2032) ($ millions)
Table 40. Rest of World DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Application (2026-2032)
Table 41. Key Market Drivers & Growth Opportunities of DMX-200 Small-Molecule CCR2 Antagonist
Table 42. Key Market Challenges & Risks of DMX-200 Small-Molecule CCR2 Antagonist
Table 43. Key Industry Trends of DMX-200 Small-Molecule CCR2 Antagonist
Table 44. Company A Company Details
Table 45. Companies Invested by Company A
Table 46. Company A Key Development and Market Layout
Table 47. Company B Company Details
Table 48. Companies Invested by Company B
Table 49. Company B Key Development and Market Layout
Table 50. Company C Company Details
Table 51. Companies Invested by Company C
Table 52. Company C Key Development and Market Layout
Table 53. Dimerix Limited Basic Information, Head Office, Major Market Areas and Its Competitors
Table 54. Dimerix Limited DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
Table 55. BioMarin Pharmaceutical Inc. Basic Information, Head Office, Major Market Areas and Its Competitors
Table 56. BioMarin Pharmaceutical Inc. DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
Table 57. ADVANZ PHARMA Corp. Limited Basic Information, Head Office, Major Market Areas and Its Competitors
Table 58. ADVANZ PHARMA Corp. Limited DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
Table 59. Taiba Middle East FZ LLC Basic Information, Head Office, Major Market Areas and Its Competitors
Table 60. Taiba Middle East FZ LLC DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
Table 61. FUSO Pharmaceutical Industries, Ltd. Basic Information, Head Office, Major Market Areas and Its Competitors
Table 62. FUSO Pharmaceutical Industries, Ltd. DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
Table 63. Everest Medicines Limited Basic Information, Head Office, Major Market Areas and Its Competitors
Table 64. Everest Medicines Limited DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
Table 1. DMX-200 Small-Molecule CCR2 Antagonist Market Size CAGR by Region (2026-2032) ($ millions)
Table 2. Major Players of Oral Small-Molecule CCR2 Antagonist
Table 3. Major Players of Other
Table 4. Global Market Size by Type (2026-2032) ($ millions)
Table 5. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Type (2026-2032)
Table 6. Major Players of Adult Patients
Table 7. Major Players of Adolescent Patients
Table 8. Major Players of Other
Table 9. Global Market Size by Patient Population (2026-2032) ($ millions)
Table 10. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Patient Population (2026-2032)
Table 11. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size by Application (2026-2032) ($ millions)
Table 12. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Application (2026-2032)
Table 13. Date of Global Key Players Enter into DMX-200 Small-Molecule CCR2 Antagonist Market
Table 14. Global Key Players DMX-200 Small-Molecule CCR2 Antagonist Product Offered
Table 15. Key Players DMX-200 Small-Molecule CCR2 Antagonist Funding/Investment (Million USD)
Table 16. Funding/Investment by Regions
Table 17. Funding/Investment by End-Industry
Table 18. Key Players DMX-200 Small-Molecule CCR2 Antagonist Valuation & Market Capitalization (Million USD)
Table 19. Key Players Mergers & Acquisitions, Expansion Plans
Table 20. DMX-200 Small-Molecule CCR2 Antagonist New Product/Technology Launches
Table 21. DMX-200 Small-Molecule CCR2 Antagonist Industry Partnerships, Agreements, and Collaborations
Table 22. DMX-200 Small-Molecule CCR2 Antagonist Industry Mergers and Acquisitions
Table 23. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size by Regions 2026-2032 ($ millions)
Table 24. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Regions 2026-2032
Table 25. United States DMX-200 Small-Molecule CCR2 Antagonist Market Size by Type (2026-2032) ($ millions)
Table 26. United States DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Type (2026-2032)
Table 27. United States DMX-200 Small-Molecule CCR2 Antagonist Market Size by Application (2026-2032) ($ millions)
Table 28. United States DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Application (2026-2032)
Table 29. Europe DMX-200 Small-Molecule CCR2 Antagonist Market Size by Type (2026-2032) ($ millions)
Table 30. Europe DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Type (2026-2032)
Table 31. Europe DMX-200 Small-Molecule CCR2 Antagonist Market Size by Application (2026-2032) ($ millions)
Table 32. Europe DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Application (2026-2032)
Table 33. China DMX-200 Small-Molecule CCR2 Antagonist Market Size by Type (2026-2032) ($ millions)
Table 34. China DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Type (2026-2032)
Table 35. China DMX-200 Small-Molecule CCR2 Antagonist Market Size by Application (2026-2032) ($ millions)
Table 36. China DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Application (2026-2032)
Table 37. Rest of World DMX-200 Small-Molecule CCR2 Antagonist Market Size by Type (2026-2032) ($ millions)
Table 38. Rest of World DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Type (2026-2032)
Table 39. Rest of World DMX-200 Small-Molecule CCR2 Antagonist Market Size by Application (2026-2032) ($ millions)
Table 40. Rest of World DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Application (2026-2032)
Table 41. Key Market Drivers & Growth Opportunities of DMX-200 Small-Molecule CCR2 Antagonist
Table 42. Key Market Challenges & Risks of DMX-200 Small-Molecule CCR2 Antagonist
Table 43. Key Industry Trends of DMX-200 Small-Molecule CCR2 Antagonist
Table 44. Company A Company Details
Table 45. Companies Invested by Company A
Table 46. Company A Key Development and Market Layout
Table 47. Company B Company Details
Table 48. Companies Invested by Company B
Table 49. Company B Key Development and Market Layout
Table 50. Company C Company Details
Table 51. Companies Invested by Company C
Table 52. Company C Key Development and Market Layout
Table 53. Dimerix Limited Basic Information, Head Office, Major Market Areas and Its Competitors
Table 54. Dimerix Limited DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
Table 55. BioMarin Pharmaceutical Inc. Basic Information, Head Office, Major Market Areas and Its Competitors
Table 56. BioMarin Pharmaceutical Inc. DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
Table 57. ADVANZ PHARMA Corp. Limited Basic Information, Head Office, Major Market Areas and Its Competitors
Table 58. ADVANZ PHARMA Corp. Limited DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
Table 59. Taiba Middle East FZ LLC Basic Information, Head Office, Major Market Areas and Its Competitors
Table 60. Taiba Middle East FZ LLC DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
Table 61. FUSO Pharmaceutical Industries, Ltd. Basic Information, Head Office, Major Market Areas and Its Competitors
Table 62. FUSO Pharmaceutical Industries, Ltd. DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
Table 63. Everest Medicines Limited Basic Information, Head Office, Major Market Areas and Its Competitors
Table 64. Everest Medicines Limited DMX-200 Small-Molecule CCR2 Antagonist Market Size (2025 VS 2031)
LIST OF FIGURES
Figure 1. Picture of DMX-200 Small-Molecule CCR2 Antagonist
Figure 2. DMX-200 Small-Molecule CCR2 Antagonist Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Growth Rate 2026-2032 ($ millions)
Figure 7. DMX-200 Small-Molecule CCR2 Antagonist Market Size by Region (2025 & 2032) ($ millions)
Figure 8. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Type (2026-2032)
Figure 9. Global Oral Small-Molecule CCR2 Antagonist Market Size Growth Rate
Figure 10. Global Other Market Size Growth Rate
Figure 11. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Patient Population (2026-2032)
Figure 12. Global Adult Patients Market Size Growth Rate
Figure 13. Global Adolescent Patients Market Size Growth Rate
Figure 14. DMX-200 Small-Molecule CCR2 Antagonist in Focal Segmental Glomerulosclerosis, FSGS
Figure 15. Global DMX-200 Small-Molecule CCR2 Antagonist Market: Focal Segmental Glomerulosclerosis, FSGS (2026-2032) ($ millions)
Figure 16. DMX-200 Small-Molecule CCR2 Antagonist in Other
Figure 17. Global DMX-200 Small-Molecule CCR2 Antagonist Market: Other (2026-2032) ($ millions)
Figure 18. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Application (2026-2032)
Figure 19. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size in Focal Segmental Glomerulosclerosis, FSGS Growth Rate
Figure 20. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size in Other Growth Rate
Figure 21. Funding/Investment
Figure 22. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Regions 2026-2032
Figure 23. United States DMX-200 Small-Molecule CCR2 Antagonist Market Size 2026-2032 ($ millions)
Figure 24. China DMX-200 Small-Molecule CCR2 Antagonist Market Size 2026-2032 ($ millions)
Figure 25. Europe DMX-200 Small-Molecule CCR2 Antagonist Market Size 2026-2032 ($ millions)
Figure 26. Rest of World DMX-200 Small-Molecule CCR2 Antagonist Market Size 2026-2032 ($ millions)
Figure 27. United States DMX-200 Small-Molecule CCR2 Antagonist Consumption Market Share by Type in 2030
Figure 28. United States DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Application in 2030
Figure 29. Europe DMX-200 Small-Molecule CCR2 Antagonist Consumption Market Share by Type in 2030
Figure 30. Europe DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Application in 2030
Figure 31. China DMX-200 Small-Molecule CCR2 Antagonist Consumption Market Share by Type in 2030
Figure 32. China DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Application in 2030
Figure 33. Rest of World DMX-200 Small-Molecule CCR2 Antagonist Consumption Market Share by Type in 2030
Figure 34. Rest of World DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Application in 2030
Figure 1. Picture of DMX-200 Small-Molecule CCR2 Antagonist
Figure 2. DMX-200 Small-Molecule CCR2 Antagonist Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Growth Rate 2026-2032 ($ millions)
Figure 7. DMX-200 Small-Molecule CCR2 Antagonist Market Size by Region (2025 & 2032) ($ millions)
Figure 8. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Type (2026-2032)
Figure 9. Global Oral Small-Molecule CCR2 Antagonist Market Size Growth Rate
Figure 10. Global Other Market Size Growth Rate
Figure 11. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Patient Population (2026-2032)
Figure 12. Global Adult Patients Market Size Growth Rate
Figure 13. Global Adolescent Patients Market Size Growth Rate
Figure 14. DMX-200 Small-Molecule CCR2 Antagonist in Focal Segmental Glomerulosclerosis, FSGS
Figure 15. Global DMX-200 Small-Molecule CCR2 Antagonist Market: Focal Segmental Glomerulosclerosis, FSGS (2026-2032) ($ millions)
Figure 16. DMX-200 Small-Molecule CCR2 Antagonist in Other
Figure 17. Global DMX-200 Small-Molecule CCR2 Antagonist Market: Other (2026-2032) ($ millions)
Figure 18. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Application (2026-2032)
Figure 19. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size in Focal Segmental Glomerulosclerosis, FSGS Growth Rate
Figure 20. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size in Other Growth Rate
Figure 21. Funding/Investment
Figure 22. Global DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Regions 2026-2032
Figure 23. United States DMX-200 Small-Molecule CCR2 Antagonist Market Size 2026-2032 ($ millions)
Figure 24. China DMX-200 Small-Molecule CCR2 Antagonist Market Size 2026-2032 ($ millions)
Figure 25. Europe DMX-200 Small-Molecule CCR2 Antagonist Market Size 2026-2032 ($ millions)
Figure 26. Rest of World DMX-200 Small-Molecule CCR2 Antagonist Market Size 2026-2032 ($ millions)
Figure 27. United States DMX-200 Small-Molecule CCR2 Antagonist Consumption Market Share by Type in 2030
Figure 28. United States DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Application in 2030
Figure 29. Europe DMX-200 Small-Molecule CCR2 Antagonist Consumption Market Share by Type in 2030
Figure 30. Europe DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Application in 2030
Figure 31. China DMX-200 Small-Molecule CCR2 Antagonist Consumption Market Share by Type in 2030
Figure 32. China DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Application in 2030
Figure 33. Rest of World DMX-200 Small-Molecule CCR2 Antagonist Consumption Market Share by Type in 2030
Figure 34. Rest of World DMX-200 Small-Molecule CCR2 Antagonist Market Size Market Share by Application in 2030
